title: Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.
abstract: Chronic lymphocytic leukemia (CLL) remains incurable with chemoimmunotherapy, and allogeneic hematopoietic stem cell transplantation (HSCT) offers the potential for cure. We assessed the outcomes of 108 CLL patients undergoing first allogeneic HSCTs, 76 with reduced-intensity (RIC) and 32 with myeloablative conditioning (MAC) between 1998 and 2009 at Dana-Farber Cancer Institute. With median follow-up of 5.9 years in surviving patients, the 5-year overall survival (OS) for the entire cohort is 63% for RIC regimens and 49% for MAC regimens (P=0.18). The risk of death declined significantly starting in 2004, and we found that 5-year OS for HSCT between 2004 and 2009 was 83% for RIC regimens compared with 47% for MAC regimens (P=0.003). For RIC transplantation, we developed a prognostic model based on predictors of progression-free survival (PFS), specifically remission status, lactate dehydrogenase, comorbidity score and lymphocyte count, and found 5-year PFS to be 83% for Score 0, 63% for Score 1, 24% for Score 2 and 6% for Score ≥3 (P<0.0001). We conclude that RIC HSCT for CLL in the current era is associated with excellent long-term PFS and OS, and, as potentially curative therapy, should be considered early in the disease course of relapsed high-risk CLL patients.
authors.affiliation: Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. jbrown2@partners.org
authors.forename: J R
authors.initials: JR
authors.lastname: Brown
authors.forename: H T
authors.initials: HT
authors.lastname: Kim
authors.forename: P
authors.initials: P
authors.lastname: Armand
authors.forename: C
authors.initials: C
authors.lastname: Cutler
authors.forename: D C
authors.initials: DC
authors.lastname: Fisher
authors.forename: V
authors.initials: V
authors.lastname: Ho
authors.forename: J
authors.initials: J
authors.lastname: Koreth
authors.forename: J
authors.initials: J
authors.lastname: Ritz
authors.forename: C
authors.initials: C
authors.lastname: Wu
authors.forename: J H
authors.initials: JH
authors.lastname: Antin
authors.forename: R J
authors.initials: RJ
authors.lastname: Soiffer
authors.forename: J G
authors.initials: JG
authors.lastname: Gribben
authors.forename: E P
authors.initials: EP
authors.lastname: Alyea
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007621:Karyotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous